Grip Molecular Technologies Inc.

Saint Paul, MN

UEI
NXXSC2FSQCS6
CAGE
8HYN0
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
1000 Westgate Dr #122, St Paul, MN 55114, USA
Founded
2019
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 -$291,355

Contract awards

Similar vendors

About the company

Grip Molecular Technologies Inc. is a biotechnology company that specializes in developing at-home medical diagnostics using next-generation graphene biosensors to provide lab-grade diagnostic results without the need for centralized laboratories. It is registered as a corporate entity and self-certified small disadvantaged business.

Grip Molecular Technologies Inc. has provided research and development services through a prime federal contract award from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The $354,267.22 firm fixed price definitive contract involved research and development of ultra-sensitive photonic integrated circuit detection of Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A antigens using graphene biosensors to support home-based diagnostics for acute SARS-CoV-2 infection. The performance took place in St. Paul, Minnesota over a period of one year from July 2022 through October 2023.

Grip Molecular Technologies Inc. has also provided services through sub-federal grant awards from the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) program, where Emory University was the prime grantee. The description of the sub-award indicates that the work involved microsystems engineered point-of-care technologies, which aligns with Grip Molecular Technologies Inc.'s focus on at-home medical diagnostics using advanced biosensor technology.

Quick answers

Is Grip Molecular Technologies Inc. registered in SAM.gov?

Yes. Grip Molecular Technologies Inc.'s SAM.gov registration is active through June 15, 2027.

What is Grip Molecular Technologies Inc.'s CAGE code?

Grip Molecular Technologies Inc.'s CAGE code is 8HYN0, and its Unique Entity ID (UEI) is NXXSC2FSQCS6.

What is Grip Molecular Technologies Inc.'s most recent federal award?

Grip Molecular Technologies Inc.'s most recent federal contract award is Research and development of ultra-sensitive PON detection of sars-COV-2 and influenza a antigens using graphene… (75A50122C00039), from Office of the Assistant Secretary for Preparedness and Response, on July 28, 2022.

On GovTribe

See Grip Molecular Technologies Inc.'s full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors

Find teaming partners on GovTribe